bluuebunny/crossref_metadata_2025_split huggingface dataset:
Augmentation of thyrotropin-induced iodide uptake in FRTL-5 cells by immunoglobulins containing blocking thyrotropin-receptor antibodies under NaCl-depleted conditions
Authors: Takeuchi Ryo , Kasagi Kanji , Hidaka Akinari , Miyamoto Shinichi , Misaki Takashi , lida Yasuhiro , Konishi Junji 
Published: December 2008

Takeuchi R, Kasagi K, Hidaka A, Miyamoto S, Misaki T, lida Y, Konishi J. Augmentation of thyrotropin-induced iodide uptake in FRTL-5 cells by immunoglobulins containing blocking thyrotropin-receptor antibodies under NaCl-depleted conditions. Eur J Endocrinol 1995;132:109–17. ISSN 0804–4643
We have found recently that Graves' immunoglobulins (Igs) are more active under NaCl-free conditions to increase iodide uptake in FRTL-5 thyroid cells. The present study was designed to examine the effect of blocking-type thyrotropin (TSH)-receptor antibodies (TR-abs) in the same assay. FRTL-5 cells were incubated with crude Ig fractions from 13 patients with primary hypothyroidism having blocking TR-abs and 100 mU/l bovine TSH in NaCl-free Hanks' balanced salt solution (HBSS) supplemented with 274 mmol/l sucrose (HBBS(−)-sucrose to keep isotonicity for 3 days, followed by the determination of 60 min of 125I uptake in the cells. Thyrotropin alone increased the uptake to 3.3-to 5.2-fold of the basal. When the highest concentration (250 ml serum equivalent (eq.)/l) of the Ig was used, the TSH-stimulated 125I uptake was decreased to 0–42% in 11 of the 13 cases. When the lower concentrations (0.4–50 ml serum eq./l) were used, however, 125I uptake was enhanced (1.4- to 11.4-fold) unexpectedly in all 13 cases. Such an enhancement was specific to blocking TR-abs, because the effect was duplicated by the purified IgG but not by Igs from 10 healthy control subjects or from three TR-ab-negative hypothyroid patients. When Graves' Igs, instead of TSH, were used as a stimulator, the similar stimulatory effect of the Ig with blocking activity was observed on the 125I uptake induced by three Graves' Igs but not on the response to one Graves' Ig. These Igs alone displayed no stimulating activity. When isotonic 5H medium was used instead of HBSS(−)-sucrose, effects of these 13 Igs were only inhibitory on the TSH-stimulated 125I uptake. In summary, Igs containing blocking TR-abs from patients with primary hypothyroidism showed a variable effect on TSH- or Graves' Ig-induced 125I uptake, depending on their concentration and the presence of NaCl. Together with our recent reports that both stimulating and blocking TR-abs exist simultaneously in some patients, these observations suggest that the two types of TR-abs and TSH may play a more complicated role in disease expression than what has been suggested as merely a net activity.
Kanji Kasagi, Department of Nuclear Medicine, Kyoto University School of Medicine, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-01, Japan
Impaired response of atrial natriuretic peptide to acute water load in obesity and in anorexia nervosa
Authors: Baranowska Bogusława , Wasilewska-Dziubińska Elżbieta , Radzikowska Małgorzata , Płonowski Artur , Roguski Krzysztof 
Published: December 2008

Baranowska B, Wasilewska-Dziubińska E, Radzikowska M, Płonowski A, Roguski K. Impaired response of atrial natriuretic peptide to acute water load in obesity and in anorexia nervosa. Eur J Endocrinol 1995;132:147–51. ISSN 0804–4643
Plasma atrial natriuretic peptide (ANP) concentrations were determined in basal conditions and after infusion of 1000 ml of 0.9% NaCl in women with anorexia nervosa, in normotensive obese women and in healthy women of the control group. Additionally, in the obese women and in the controls, plasma ANP was measured after iv injection of clonidine. Anorectic patients were investigated in the period of weight loss (mean deficit of body weight was 40%). The mean body mass index (BMI) in the obese women was 36.44 ± 0.36 kg/m2. Basal plasma ANP concentrations were significantly higher in both anorectic and obese women (p < 0.001 and p < 0.01, respectively). The response of ANP to acute water load was markedly blunted in anorexia nervosa and in obesity (Δ% = 232% in control group, 14% in anorexia nervosa and 21% in obesity. A significant increase of ANP was found after iv injection of clonidine in the control group and in obesity (p < 0.001 and p < 0.01, respectively). However, the increase of response (expressed as a percentage change) in obese patients was lower than that in the control group (Δ% = 64% and 199%, respectively). The response of ANP to α2-adrenergic stimulation was higher than to hemodynamic stimulus. Our results suggest that the disturbed control of neuropeptides and neurotransmitters as well as changes in peripheral metabolism may explain the impaired responsibility of ANP to hemodynamic stimuli in anorectic and obese patients.
Department of Neuroendocrinology, Medical Center of Postgraduate Education, Fieldorfa 40, 04-158 Warsaw, Poland
Lack of growth hormone response to acute administration of dexamethasone in anorexia nervosa
Authors: Scacchi Massimo , Invitti Cecilia , Pincelli Angela I , Pandolfi Claudio , Dubini Antonella , Cavagnini Francesco 
Published: December 2008

Scacchi M, Invitti C, Pincelli AI, Pandolfi C, Dubini A, Cavagnini F. Lack of growth hormone response to acute administration of dexamethasone in anorexia nervosa. Eur J Endocrinol 1995;132:152–8. ISSN 0804–4643
High plasma growth hormone (GH) levels, associated with abnormal hormone responses to provocative stimuli, point to an altered GH secretion in anorexia nervosa. The GH-releasing effect of acutely administered glucocorticoids, firmly established in normal subjects, has not been reported in these patients. In this study, acute iv administration of 4 mg of dexamethasone, compared with saline, increased plasma GH in nine normal-weight women (AUC 848.2 ± 127.95 vs 242.8 ± 55.35 μg·l−1·min−1, p < 0.05, respectively) but was ineffective in 11 anorectic patients (AUC 3271.8 ± 1407.11 vs 2780.0 ± 1162.04 μg·l−1·min−1, NS). After dexamethasone, a significant lowering of plasma cortisol was observed in normal women (AUC 25367.0 ± 3128.43 vs 47347.1 ± 4456.61 nmol·l−1·min−1, after dexamethasone and saline, respectively, p < 0.05), but not in anorectic patients (AUC 77809.3 ± 8499.92 vs 78454.9 ± 7603.62 nmol·l−1·min−1, NS). In both groups, plasma adrenocorticotrophin (ACTH) displayed a significant decrease after dexamethasone (AUC 523.6 ± 92.08 vs 874.2 ± 115.03 pmol·l−1·min−1, p < 0.05, after dexamethasone and saline, respectively, in anorectic patients and 377.5 ± 38.41 vs 1004.9 ± 200.51 pmol·l−1·min−1, p < 0.05, in controls). However, when considering the hormonal decremental areas, a significant dexamethasone-induced ACTH inhibition, compared to saline, was evidenced in normal (ΔAUC –414.4 ± 65.75 vs 222.9 ± 42.40 pmol·l−1·min−1, p < 0.05) but not in anorectic women (ΔAUC –254.2 ± 96.92 vs 2.9 ± 132.32 pmol·l−1·min−1, NS). In conclusion, compared to normal subjects, anorectic patients do not display an increase of plasma GH levels and show a lower degree of inhibition of the hypothalamic–pituitary–adrenal axis following acute iv administration of dexamethasone. This observation broadens the array of the abnormal GH responses to provocative stimuli in anorexia nervosa and supports the existence, in these patients, of a decreased hypothalamic somatostatin secretion, although the possibility of a reduced tissue sensitivity to glucocorticoids cannot be excluded.
Francesco Cavagnini, 2nd Chair of Endocrinology, University of Milan, Istituto Scientifico Ospedale San Luca, Centro Auxologico Italiano, via Spagnoletto 3, 20149 Milano, Italy
Effect of growth hormone therapy in men with severe idiopathic oligozoospermia
Authors: Lee Kok-Onn , Ng Soon-Chye , Lee Pheng-Soon , Bongso Ariff T , Taylor Elizabeth A , Lin Ting-Kwong , Ratnam Shan S 
Published: December 2008

Lee K-O, Ng S-C, Lee P-S, Bongso AT, Taylor EA, Lin T-K, Ratnam SS. Effect of growth hormone therapy in men with severe idiopathic oligozoospermia. Eur J Endocrinol 1995;132:159–62. ISSN 0804–4643
Some studies have suggested that growth hormone (GH) may enhance folliculogenesis in women, and similarly may enhance spermatogenesis in men with hypogonadotrophic hypogonadism. In this prospective open-controlled pilot study, we investigated the effect of daily subcutaneous GH for 5 months in 12 endocrinologically normal men with severe idiopathic oligozoospermia (< 10 million/ ml). All the men had normal karyotype and endocrine tests, including a GH response of > 20 000 mU/l to insulin hypoglycaemia. Nine men with similar sperm counts acted as controls. During treatment, each patient was examined monthly, asked for side effects and had glycosylated haemoglobin, glucose and blood counts monitored. Five semen samples were obtained in the 4 months before treatment, two samples per month during treatment and three samples after stopping treatment. The mean insulinlike growth factor I (IGF-I) was normal before treatment and 1 month after ending treatment, at 206 and 182 μg/l, respectively, but increased significantly during treatment to 444 μg/l (p < 0.0001, ANOVA). The mean (sd) sperm counts were 2.6 (2.5), 2.5 (3.7) and 2.3 (2.1) million/ml before, during and after GH treatment, respectively, and did not show any statistically significant differences (ANOVA). We conclude that GH does not increase or decrease sperm counts in men with severe idiopathic oligozoospermia.
K-O Lee, Division of Endocrinology, Department of Medicine, National University of Singapore, Kent Ridge, Singapore 0511
Urinary iodine excretion and individual iodine supplementation among elderly subjects: A cross-sectional investigation in the commune of Randers, Denmark
Authors: Pedersen Klaus M , Iversen Eigil , Laurberg Peter 
Published: December 2008

Pedersen KM, Iversen E, Laurberg P. Urinary iodine excretion and individual iodine supplementation among elderly subjects. A cross-sectional investigation in the commune of Randers, Denmark. Eur J Endocrinol 1995;132:171–4. ISSN 0804–4643
Several studies have demonstrated that the iodine intake is relatively low in Denmark. However, the results are difficult to interpret because no information has been given on the frequency of individual iodine supplementation. We performed a cross-sectional study of elderly subjects living in the commune of Randers, Denmark. Urinary iodine excretion was measured in the 423 participants (185 males, 238 females) and a careful history was taken on any possible intake of supplementary iodine. The median urinary iodine excretion was 48.3 μg/g creatinine for the whole population (40.8 μg/g creatinine in males, 53.2 μg/g creatinine in females). In the part of the population that did not take iodine supplementation (46.7%) the median value was 36.1 μg/g creatinine (males 33.8; females 38.8). Regular iodine supplementation taken as an iodine-containing vitamin/mineral tablet was found in 30.8% of the population. This increased the urinary iodine excretion to a median level of 80.5 μg/g creatinine (males 62.0; females 88.0). The study shows that the basic iodine intake level is overestimated if individual iodine supplementation is not taken into account. Such supplementation may lead to median iodine excretion values that seem reasonable, even if the iodine intake of the part of the population not taking iodine (in this study, nearly half of the population) is low.
Klaus Pedersen, Department of Internal Medicine and Endocrinology, Aalborg Hospital, Reberbansgade, DK-9000 Aalborg, Denmark
Impaired natural killer cytotoxicity in peripheral blood mononuclear cells in Graves' disease
Authors: Marazuela Mónica , Vargas Juan A , Alvarez-Mon Melchor , Albarrán Fernando , Lucas Tomás , Durántez Alberto 
Published: December 2008

Marazuela M, Vargas JA, Alvarez-Mon M, Albarrán F, Lucas T, Durántez A. Impaired natural killer cytotoxicity in peripheral blood mononuclear cells in Graves' disease. Eur J Endocrinol 1995;132:175–80. ISSN 0804–4643
We studied the natural killer (NK) activity of peripheral blood mononuclear cells (PBMC) in patients with Graves' disease (GD). Peripheral blood mononuclear cells from 20 untreated hyperthyroid patients with GD showed a significantly reduced NK activity against 51 Cr-labeled K562 cells (33.9 ± 15.9%), while in 32 euthyroid patients under antithyroid drug therapy, NK activity was similar to that of controls (46.9 ± 17.3 and 49.9 ± 20.2%, respectively). Furthermore, normalization of thyroid function with antithyroid drugs was associated with a significant increase and normalization of NK activity during the follow-up of nine GD patients (from 29.2 ± 17.9 to 48.1 ± 16.5%). This phenomenon could not be ascribed to a defective number of NK cells because the amounts of CD56 + and CD16 + cells in PBMC from both hyperthyroid and euthyroid GD patients were within normal ranges. Natural killer activity of PBMC from patients with toxic multinodular goiter was similar to that of normal controls (45 ± 12.8 to 49.9 ± 20%). No correlation was found between natural killer activity and serum levels of free thyroxine, TSH-inhibitory immunoglobulins, thyroidal antibodies to thryoglobulin and thyroidal microsomal antigen, dose or duration of antithyroid drug therapy. Natural killer activity from both controls and GD patients was enhanced in vitro by addition of recombinant interleukin 2 (IL-2), reaching control levels in hyperthyroid patients. These abnormalities were not associated with a defective IL-2 production by T cells, nor with a decreased IL-2R expression. We conclude that in untreated Graves' disease there is a decrease in NK cell activity in PBMC, probably dependent on the autoimmune process. Possible biological and clinical implications are discussed.
Monica Marazuela, Hospital de la Princesa, c/Diego de Léon 62, Madrid 28006, Spain
Identification of luteinizing hormone receptor binding inhibitor in bovine corpora lutea
Authors: Rathnam Premila , Lin Shou-qing , Saxena Brij B 
Published: December 2008

Rathnam P, Lin S, Saxena BB. Identification of luteinizing hormone receptor binding inhibitor in bovine corpora lutea. Eur J Endocrinol 1995;132:213–17. ISSN 0804–4643
A 7000 g supernatant, obtained during the purification of luteinizing hormone (LH) receptor from bovine corpora lutea homogenate, was concentrated by ultrafiltration. The filtrate, containing < 50 000 molecular weight material, exhibited LH receptor binding inhibitor (LH-RBI) activity. The filtrate was ultrafiltered sequentially through Amicon PM-10, PM-30 and UM-2 filters to yield a LH-RBI-containing fraction in the higher molecular weight range of 30 000–10 000 and a LH-RBI-containing fraction in the lower molecular weight range of 10 000–1000. The higher molecular weight LH-RBI fraction was purified on Sephadex G-25 and the lower molecular weight LH-RBI fraction was purified on Sephadex G-50. Both the high- and the low-molecular-weight LH-RBI species inhibited the binding of 125I-labeled human chorionic gonadotropin (hCG) to bovine corpora lutea and to rat Leydig cell membrane receptors. Similarly, the production of testosterone by hCG-stimulated rat Leydig cells was inhibited in a dose–response manner by both the high- and the low-molecular-weight LH-RBI species. The LH-RBI activity in the low-molecular-weight species was stable at 4°C for up to 6 months and at temperatures up to 90°C for 15 mins, whereas the LH-RBI activity of the high-molecular-weight species was stable at 4°C for 15 months and unstable at 60°C after 15 min. The 7000 g supernatant provided a much-needed source to obtain larger than previously reported quantities of LH-RBI for isolation as well as for structure and function studies.
Brij B Saxena, Cornell Univ. Medical College, Rm A-267, 1300 York Ave, New York, NY 10021, USA
Follow-up study on the effects of thyroid hormone administration on androgen metabolism of peripubertal rat Sertoli cells
Authors: Panno ML , Salerno M , Lanzino M , De Luca G , Maggiolini M , Straface SV , Prati M , Palmero S , Bolla E , Fugassa E , Andò S 
Published: December 2008

Panno ML, Salerno M, Lanzino M, De Luca G, Maggiolini M, Straface SV, Prati M, Palmero S, Bolla E, Fugassa E, Andò S. Follow-up study on the effects of thyroid hormone administration on androgen metabolism of peripubertal rat sertoli cells. Eur J Endocrinol 1995;132:236–41. ISSN 0804–4643
The inhibitory effect of triiodothyronine (T3) given in early postnatal life on Sertoli cell proliferative activity, leading to their precocious terminal differentiation, has been demonstrated previously. However, data concerning the role of thyroid hormone on androgen metabolism of Sertoli cells during the same period are still lacking. In this study we performed a time-course investigation on the effects of T3 treatment on testosterone metabolism in Sertoli cells isolated from 2-, 3- and 4-weeks-old euthyroid rats. Triiodothyronine (3 μg/100 g body wt) was given ip., during the last week prior to sacrifice. Sertoli cells from all animal groups initially were cultured under basal conditions during the first 24 h and subsequently in the presence of testosterone (0.5 μmol/l) with or without T3 (1 nmol/l) for an additional 24 h. This treatment given to 2-week-old animals resulted in reduced testicular growth. As far as androgen metabolism is concerned, T3 in vivo and in vitro treatment in 2- and 3-week-old animals induced a lowering of dihydrotestosterone ± 3α-diol with an enhancement of the two other 5α-reduced androgens. The effect was much less pronounced in the oldest group. In both 2-and 3-week-old treated rats a marked reduction of oestradiol was observed, which indicates an inhibition of aromatase activity, mainly in younger animals. This enzyme has been reported to be extremely active in Sertoli cells of rats (of the same strain) between the age of 5 and 20 days, but it decreases rapidly thereafter. The results suggest that T3 given in early postnatal life could modify directly the androgen metabolism in Sertoli cells.
Sebastiano Andò, Cattedra di Fisiopatologia Endocrina, Dipartimento di Biologia Cellulare, Università della Calabria, 87030 Arcavacata di Rende, Cosenza, Italy
Dexamethasone therapy is associated with a rise in urinary epidermal growth factor concentrations in the preterm infant
Authors: Scott Susan M , Rogers Cathy , Backstrom Conra 
Published: December 2008

Scott SM, Rogers C, Backstrom C. Dexamethasone therapy is associated with a rise in urinary epidermal growth factor concentrations in the preterm infant. Eur J Endocrinol 1995;132:326–30. ISSN 0804–4643
The effect of glucocorticoid hormones on epidermal growth factor (EGF) concentrations has not been described in the premature infant. We examined this relationship in a group of infants treated with dexamethasone for airway edema (three to five doses) or chronic lung disease (six weeks of a tapering protocol). We collected urinary samples in 45 infants (25 for airway edema, 20 for chronic lung disease) before, during and after the use of dexamethasone. The EGF values were unchanged in infants that were given dexamethasone for airway edema. In contrast, all infants treated for chronic lung disease increased their EGF values by 1 week of therapy. At the end of the dexamethasone taper, ten of the infants had recovered successfully from ventilatory support. This group of infants had post-therapy EGF values that were significantly higher than pretherapy values. In the ten infants that were still ventilator dependent at the end of therapy, EGF values were not different from pretherapy values. We conclude that dexamethasone therapy was associated with an increase in urinary EGF values in the preterm infant treated for at least 1 week. The positive correlation of tapering from ventilatory support with increases in EGF values suggests that EGF may be a marker of dexamethasone effect or an effector of dexamethasone action.
Susan M Scott, University of New Mexico, School of Medicine, Department of Pediatrics, ACC 3-West, Albuquerque, NM 87131-5311, USA
Effect of streptozotocin injection on expression of immunoreactive foilistatin and βA and βB subunits of inhibin/activin in rat pancreatic islets
Authors: Ogawa Kenji , Ono Kenichiro , Kurohmaru Masamichi , Hayashi Yoshihiro 
Published: December 2008

Ogawa K, Ono K, Kurohmaru M, Hayashi Y. Effect of streptozotocin injection on expression of immunoreactive follistatin and βA and βB subunits of inhibin/activin in rat pancreatic islets. Eur J Endocrinol 1995;132:363–9. ISSN 0804–4643
The effect of streptozotocin (STZ) on expression of immunoreactive follistatin and β-subunits of inhibin/activin in pancreatic islets was studied by immunohistochemistry. To localize immunoreactive follistatin in pancreatic islets, two different anti-follistatin sera were used. Anti-follistatin(300–315) serum detects only long-form follistatin, while anti-follistatin(123–134) serum detects both long- and C-terminal truncated short-form follistatin in sodium dodecyl sulfate polyacrylamide gel electrophoresis and immunoblotting. Although an intense reaction with anti-follistatin(123–134) was found in pancreatic B cells, a reaction with anti-follistatin(300–315) was not present in any type of cells. This result suggests that only short-form follistatin is expressed in pancreatic islets. It was confirmed that immunoreaction with anti-βA(1–10)-Tyr serum was found in pancreatic B cells. The anti-βB(1–10)-Tyr reaction was intense in A cells but weak in B cells. These findings suggest that the expression pattern of each β-subunit differs in each type of islet cells. At 2 weeks after STZ injection (65 mg/kg), insulin immunoreaction still remained in B cells, although most pancreatic B cells were destroyed. In contrast, immunoreactions of follistatin and β-subunits in B cells disappeared 24 h after STZ treatment. These results indicate that STZ affects the production of follistatin or β-subunits of inhibin/activin in pancreatic B cells rather than insulin secretion.
Kenji Ogawa, Department of Veterinary Anatomy, Faculty of Agriculture, The University of Tokyo, Bunkyo-ku, Tokyo 113, Japan